News - Antibiotics and Infectious diseases, Biotechnology


Popular Filters

1 to 25 of 31 results

ICBA adopts antimicrobial resistance as an inaugural priority, proposed by BIA

ICBA adopts antimicrobial resistance as an inaugural priority, proposed by BIA


At the inaugural meeting of the newly formed International Council of Biotech Associations (ICBA) which…

Antibiotics and Infectious diseasesBiotechnologyGlobalHealthcareResearch

Debiopharm signs deal with Nobelex Biotech over antibiotics

Debiopharm signs deal with Nobelex Biotech over antibiotics


Swiss pharma company Debiopharm Group and Canadian biotech company Nobelex Biotech have announced a collaboration…

Antibiotics and Infectious diseasesBiotechnologyCanadaDebiopharmLicensingNobelex Biotech

Helperby Therapeutics and Cadila make progress on first antibiotic resistance breaker

Helperby Therapeutics and Cadila make progress on first antibiotic resistance breaker


Helperby Therapeutics, a spin-out drug discovery company from St George’s University of London, UK,…

Antibiotic resistanceAntibioticsAntibiotics and Infectious diseasesBiotechnologyCadila PharmaceuticalsHelperby TherapeuticsIndiaUK

BioVersys links with GSK and others to develop preclinical candidates in tuberculosis


Privately-held Swiss biotech company BioVersys has entered a collaboration with UK pharma giant GlaxoSmithKline…

Antibiotics and Infectious diseasesBiotechnologyBioVersysGlaxoSmithKlineResearchWELLCOME TRUST

Taiwan’s TaiGen Biotech receives domestic marketing approval for Taigexyn


Taiwan-based drug developer TaiGen Biotechnology says that the Taiwan Food and Drug Administration has…

Antibiotics and Infectious diseasesAsia-PacificBiotechnologyRegulationTaiGen BiotechTaigexyn

Argenta and Antabio meet milestone in anti-bacterial drug discovery collaboration

Argenta and Antabio meet milestone in anti-bacterial drug discovery collaboration


Drug discovery company Argenta, a subsidiary of Belgian drugmaker Galapagos (Euronext: GLPG), has achieved…

Antibiotics and Infectious diseasesArgentaBiotechnologyFranceResearchUK

Valneva initiates fourth antibody discovery program for Sanofi Pasteur


European biotechnology company Valneva has initiated a fourth monoclonal antibody discovery program for…

Antibiotics and Infectious diseasesBiotechnologyLicensingResearchSanofiSanofi PasteurVaccinesValneva

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C

Gilead files for US approval of ledipasvir/sofosbuvir combination for hepatitis C


US biotech major Gilead Sciences has submitted a New Drug Application (NDA) to the US Food and Drug Administration…

Antibiotics and Infectious diseasesBiotechnologyGilead SciencesledipasvirRegulationsofosbuvirUSA

Lophius Biosciences Appoints Dr Robert Phelps as director of business operations


German biotechnology company Lophius Biosciences GmbH has announced that Dr Robert Phelps has joined…

Antibiotics and Infectious diseasesBiotechnologyBoardroomEuropeImmunologicals

Valneva updates on Phase II/III interim analysis of its Pseudomonas aeruginosa vaccine candidate


Biotech firm Valneva has provided an update on the Phase II/III efficacy study interim analysis of its…

Antibiotics and Infectious diseasesBiotechnologyResearchValneva

Terms amended in Bellus' acquisition of Thallion


Canada-based drugmaker Bellus Health (TSX: BLU) has amended its agreement to acquire fellow Canadian…

Antibiotics and Infectious diseasesBellus HealthBiotechnologyMergers & AcquisitionsNorth AmericaShigamabsThallion Pharmaceuticals

QIDP designation for Tetraphase's lead antibiotic candidate


The US Food and Drug Administration has designated biotech company Tetraphase Pharmaceuticals' (Nasdaq:…

Antibiotics and Infectious diseasesBiotechnologyeravacyclineNorth AmericaRegulationTetraphase Pharmaceuticals

Briefs: Added use for Theravance's Vibativ; approval sought for ViiV dolutegravir; FDA accepts Pfizer sNDA for Xeljanz


USA-based Theravance (Nasdaq: THRX) says that the US Food and Drug Administration has approved the firm's…

Anti-Arthritics/RheumaticsAnti-viralsAntibiotics and Infectious diseasesBiotechnologydolutegravirNorth AmericaPfizerPharmaceuticalRegulationTheravanceVibativViiV HealthcareXeljanz

NovaBay Pharmaceuticals: tuning in for a crescendo of data, say analysts


US biotech firm NovaBay Pharmaceutical's (Nasdaq: NBY) first-quarter 2013 results set the scene for a…

Antibiotics and Infectious diseasesauricloseneBiotechnologyFinancialGenito-urinaryNovaBay PharmaceuticalNVC-422OphthalmicsResearch

Soligenix and Intrexon collaborate on Melioidosis therapy development


US clinical stage biopharma company Soligenix (OTCBB: SNGX) says it will jointly develop a treatment…

Antibiotics and Infectious diseasesBiotechnologyIntrexonLicensingPharmaceuticalResearchSoligenix

Termination of Shigamabs deal with LFB Biotech leads Thallion to review options


Canada-based Thallion Pharmaceuticals (TSX VENTURE: TLN) and LFB Biotechnologies of France have terminated…

Antibiotics and Infectious diseasesBiotechnologyLFB BiotechnologiesLicensingShigamabsThallion Pharmaceuticals

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK


NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

South Africa awards 5.9 billion-rand antivirals tender; Panacela Russian contract


The South African government has announced a 5.9 billion rand ($665 million) tender awarded to three…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesBiotechnologyCipla MedproCleveland BioLabsFinancialGeneralMylan LaboratoriesPanacela LabsRest of the WorldXenomycins

Synthetic Biologics to acquire clinical-stage C. diff infectious disease program


USA-based Synthetic Biologics (NYSE: SYN), a developer of synthetic biologics and innovative medicines…

Antibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsPrev AbRSYN-004Synthetic Biologics

GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab


USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says it has agreed to amend the clinical development plan…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesraxibacumabRegulationResearch

NovaBay entering transformational period, say Edison analysts


US biotech firm NovaBay Pharmaceutical (Nasdaq: NBY) is entering a potentially transformational 12-month…

Antibiotics and Infectious diseasesBiotechnologyFinancialLicensingNeutroPhaseNovaBay PharmaceuticalNVC422Research

Edison analysts' take on Basilea outlook


The protracted development of antibiotic ceftobiprole has left Swiss biotech firm Basilea Pharmaceutica…

Antibiotics and Infectious diseasesBasilea PharmaceuticaBiotechnologyceftobiproleFinancialisavuconazoleOncologyResearchToctino

UK's NICE launches new medicines advisory service


The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) last Friday launched…

Antibiotics and Infectious diseasesAstellas PharmaBiotechnologyDificlirEuropeGenericsPharmaceuticalRegulation

Human Genome resubmits raxibacumab BLA


US biotech firm Human Genome Sciences (Nasdaq: HGSI), the subject of a hostile takeover bid from GlaxoSmithKline,…

Antibiotics and Infectious diseasesBiotechnologyHuman Genome SciencesNorth AmericaraxibacumabRegulation

1 to 25 of 31 results

Back to top